ProCE Banner Activity

PILLAR: Efficacy and Persistence of Long-Acting Cabotegravir in Real-world Phase IV Trial of HIV PrEP

Conference Coverage
Slideset

This analysis of the phase IV PILLAR study found that HIV pre-exposure prophylaxis with long-acting cabotegravir in men who have sex with men and transgender men for 12 months was 100% effective with high persistence.

Released: March 13, 2025

Expiration: September 12, 2025

Share

Provided by

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare